



Press Release

Friday, July 30, 2010

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE: STAR

STRIDES ARCOLAB ANNOUNCES US FDA APPROVAL OF SUMATRIPTAN SUCCINATE INJECTION

–ELEVENTH STERILE INJECTABLES APPROVAL IN 2010



Strides Arcolab Limited (Strides) today announced that the U.S. Food and Drug Administration has granted approval of Sumatriptan Succinate Injection 6 mg (base)/0.5 mL, a selective agonist for a vascular 5-hydroxytryptamine₁ receptor subtype. It is used for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.

Sumatriptan will be offered as 6 mg (base)/0.5 mL, packaged in a single-use vial. According to IMS data, the total U.S. market for Sumatriptan in 2009 approximated \$ 200 million, of which the market for 6 mg (base)/0.5 mL vial injection was US\$ 16.2 million.

Sumatriptan will be launched under the partnership between Strides and Sagent Pharmaceuticals wherein Strides is developing and supplying more than 25 injectable products for the U.S. market which will be marketed by Sagent. The launch is expected in the near future.

About Sumatriptan Succinate Injection

Sumatriptan Succinate Injection is a selective 5-hydroxytryptamine₁ receptor subtype agonist with no significant affinity or pharmacological activity at 5-HT₂, 5-HT₃ receptor subtypes or at alpha₁-, alpha₂-, or beta-adrenergic; dopamine₁; dopamine₂; muscarinic; or benzodiazepine receptors. The vascular 5-HT₁ receptor subtype to which Sumatriptan binds selectively and exerts its antimigrainous effect is present on cranial arteries, on the human basilar artery and in the vasculature of the isolated dura mater of humans. In these tissues Sumatriptan activates this receptor to cause vasoconstriction, an action correlating with the relief of migraine and cluster headache.



It should not be given intravenously because of its potential to cause coronary vasospasm. Sumatriptan Injection should not be given to patients with history, symptoms or signs of ischemic cardiac, cerebrovascular, peripheral vascular syndromes or with other significant underlying cardiovascular diseases .

About Strides Arcolab Limited:

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence™ and learn more about Sagent, please visit www.SagentPharma.com.

For further information, please contact:

Mr. Ravi Seth CEO – International Operations Ph: +91 80 6658 0121	Mr. Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: maheshn@corvoshandwick.co.in
Mr. N Kannan (Investor Relations) Tel : +91 98450 54745	Ms. Kasturi Wasmatar, Corporate Voice/ Weber Shandwick Mobile: 99167 28393 Email: kasturi@corvoshandwick.co.in
Ms. Melissa Arulappan (Media) Tel: +91 98450 22389	

